Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C

Xueshu Zhang, Ruiwen Zhang, Hui Zhao, Hongying Cai, Kimberly A. Gush, Russell G. Kerr, George Pettit, Andrew S. Kraft

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Bryostatin 1, a natural product anticancer agent isolated from a marine bryozoan, has been shown in tissue culture to activate protein kinase C. This agent has recently undergone Phase I testing in humans given either as a bolus i.v. injection or a continuous infusion. To understand how bryostatin 1 might be used best as an anticancer agent, a study of the pharmacokinetics, tissue distribution, metabolism, and elimination of bryostatin 1 in mice was undertaken, using [C26-3H]-labeled bryostatin 1. Following i.v. administration, the plasma disappearance curve for bryostatin 1 could be described by a two-compartment model, with half-lives of 1.05 and 22.97 h, respectively. In contrast, the plasma disappearance curve for bryostatin 1 administered i.p. was better described by a first order absorption one- compartment model, with an absorption half-life of 0.81 h and an elimination half-life of 28.76 h, respectively. The majority of radioactivity in plasma was associated with the intact drug for up to 24 h alter dosing. In the first 12 h after i.v administration, urinary excretion represented the major pathway of elimination, with 23.0 ± 1.9% (mean ± SD) of the administered dose excreted. Within 72 h after i.v. administration, approximately equal amounts of radioactivity (40%) were excreted in fetes compared to urine. Bryostatin 1 was widely distributed in many organs but concentrated in the lung, liver, gastrointestinal tract, and fatty tissue. The concentration in the gastrointestinal tract, along with the fecal excretion, suggests the possibility of enterohepatic circulation of this drug. In summary, this study demonstrates that bryostatin 1 is relatively stable in vivo, widely distributed but concentrated in some major tissues, and rapidly excreted first through urine and at later times through the feces. The data from this animal study should be useful in the design of future human trials with this anticancer drug.

Original languageEnglish (US)
Pages (from-to)802-808
Number of pages7
JournalCancer Research
Volume56
Issue number4
StatePublished - Feb 15 1996

Fingerprint

Biological Products
Antineoplastic Agents
Protein Kinase C
Pharmacology
Radioactivity
Half-Life
Gastrointestinal Tract
Urine
Pharmaceutical Preparations
Enterohepatic Circulation
bryostatin 1
Tissue Distribution
Feces
Adipose Tissue
Pharmacokinetics
Lung
Injections
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zhang, X., Zhang, R., Zhao, H., Cai, H., Gush, K. A., Kerr, R. G., ... Kraft, A. S. (1996). Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Research, 56(4), 802-808.

Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. / Zhang, Xueshu; Zhang, Ruiwen; Zhao, Hui; Cai, Hongying; Gush, Kimberly A.; Kerr, Russell G.; Pettit, George; Kraft, Andrew S.

In: Cancer Research, Vol. 56, No. 4, 15.02.1996, p. 802-808.

Research output: Contribution to journalArticle

Zhang, X, Zhang, R, Zhao, H, Cai, H, Gush, KA, Kerr, RG, Pettit, G & Kraft, AS 1996, 'Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C', Cancer Research, vol. 56, no. 4, pp. 802-808.
Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG et al. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Research. 1996 Feb 15;56(4):802-808.
Zhang, Xueshu ; Zhang, Ruiwen ; Zhao, Hui ; Cai, Hongying ; Gush, Kimberly A. ; Kerr, Russell G. ; Pettit, George ; Kraft, Andrew S. / Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. In: Cancer Research. 1996 ; Vol. 56, No. 4. pp. 802-808.
@article{84c36a07b1694353924f80894c7be251,
title = "Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C",
abstract = "Bryostatin 1, a natural product anticancer agent isolated from a marine bryozoan, has been shown in tissue culture to activate protein kinase C. This agent has recently undergone Phase I testing in humans given either as a bolus i.v. injection or a continuous infusion. To understand how bryostatin 1 might be used best as an anticancer agent, a study of the pharmacokinetics, tissue distribution, metabolism, and elimination of bryostatin 1 in mice was undertaken, using [C26-3H]-labeled bryostatin 1. Following i.v. administration, the plasma disappearance curve for bryostatin 1 could be described by a two-compartment model, with half-lives of 1.05 and 22.97 h, respectively. In contrast, the plasma disappearance curve for bryostatin 1 administered i.p. was better described by a first order absorption one- compartment model, with an absorption half-life of 0.81 h and an elimination half-life of 28.76 h, respectively. The majority of radioactivity in plasma was associated with the intact drug for up to 24 h alter dosing. In the first 12 h after i.v administration, urinary excretion represented the major pathway of elimination, with 23.0 ± 1.9{\%} (mean ± SD) of the administered dose excreted. Within 72 h after i.v. administration, approximately equal amounts of radioactivity (40{\%}) were excreted in fetes compared to urine. Bryostatin 1 was widely distributed in many organs but concentrated in the lung, liver, gastrointestinal tract, and fatty tissue. The concentration in the gastrointestinal tract, along with the fecal excretion, suggests the possibility of enterohepatic circulation of this drug. In summary, this study demonstrates that bryostatin 1 is relatively stable in vivo, widely distributed but concentrated in some major tissues, and rapidly excreted first through urine and at later times through the feces. The data from this animal study should be useful in the design of future human trials with this anticancer drug.",
author = "Xueshu Zhang and Ruiwen Zhang and Hui Zhao and Hongying Cai and Gush, {Kimberly A.} and Kerr, {Russell G.} and George Pettit and Kraft, {Andrew S.}",
year = "1996",
month = "2",
day = "15",
language = "English (US)",
volume = "56",
pages = "802--808",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C

AU - Zhang, Xueshu

AU - Zhang, Ruiwen

AU - Zhao, Hui

AU - Cai, Hongying

AU - Gush, Kimberly A.

AU - Kerr, Russell G.

AU - Pettit, George

AU - Kraft, Andrew S.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Bryostatin 1, a natural product anticancer agent isolated from a marine bryozoan, has been shown in tissue culture to activate protein kinase C. This agent has recently undergone Phase I testing in humans given either as a bolus i.v. injection or a continuous infusion. To understand how bryostatin 1 might be used best as an anticancer agent, a study of the pharmacokinetics, tissue distribution, metabolism, and elimination of bryostatin 1 in mice was undertaken, using [C26-3H]-labeled bryostatin 1. Following i.v. administration, the plasma disappearance curve for bryostatin 1 could be described by a two-compartment model, with half-lives of 1.05 and 22.97 h, respectively. In contrast, the plasma disappearance curve for bryostatin 1 administered i.p. was better described by a first order absorption one- compartment model, with an absorption half-life of 0.81 h and an elimination half-life of 28.76 h, respectively. The majority of radioactivity in plasma was associated with the intact drug for up to 24 h alter dosing. In the first 12 h after i.v administration, urinary excretion represented the major pathway of elimination, with 23.0 ± 1.9% (mean ± SD) of the administered dose excreted. Within 72 h after i.v. administration, approximately equal amounts of radioactivity (40%) were excreted in fetes compared to urine. Bryostatin 1 was widely distributed in many organs but concentrated in the lung, liver, gastrointestinal tract, and fatty tissue. The concentration in the gastrointestinal tract, along with the fecal excretion, suggests the possibility of enterohepatic circulation of this drug. In summary, this study demonstrates that bryostatin 1 is relatively stable in vivo, widely distributed but concentrated in some major tissues, and rapidly excreted first through urine and at later times through the feces. The data from this animal study should be useful in the design of future human trials with this anticancer drug.

AB - Bryostatin 1, a natural product anticancer agent isolated from a marine bryozoan, has been shown in tissue culture to activate protein kinase C. This agent has recently undergone Phase I testing in humans given either as a bolus i.v. injection or a continuous infusion. To understand how bryostatin 1 might be used best as an anticancer agent, a study of the pharmacokinetics, tissue distribution, metabolism, and elimination of bryostatin 1 in mice was undertaken, using [C26-3H]-labeled bryostatin 1. Following i.v. administration, the plasma disappearance curve for bryostatin 1 could be described by a two-compartment model, with half-lives of 1.05 and 22.97 h, respectively. In contrast, the plasma disappearance curve for bryostatin 1 administered i.p. was better described by a first order absorption one- compartment model, with an absorption half-life of 0.81 h and an elimination half-life of 28.76 h, respectively. The majority of radioactivity in plasma was associated with the intact drug for up to 24 h alter dosing. In the first 12 h after i.v administration, urinary excretion represented the major pathway of elimination, with 23.0 ± 1.9% (mean ± SD) of the administered dose excreted. Within 72 h after i.v. administration, approximately equal amounts of radioactivity (40%) were excreted in fetes compared to urine. Bryostatin 1 was widely distributed in many organs but concentrated in the lung, liver, gastrointestinal tract, and fatty tissue. The concentration in the gastrointestinal tract, along with the fecal excretion, suggests the possibility of enterohepatic circulation of this drug. In summary, this study demonstrates that bryostatin 1 is relatively stable in vivo, widely distributed but concentrated in some major tissues, and rapidly excreted first through urine and at later times through the feces. The data from this animal study should be useful in the design of future human trials with this anticancer drug.

UR - http://www.scopus.com/inward/record.url?scp=0030063389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030063389&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 802

EP - 808

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -